Company / Cost of Revenue
ResMed Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$2.1B
FY2025
5-year range
$1.4B / $2.1B
FY2021-FY2025
Trend
+3.0%
vs FY2024
Sector context
#26 of 107
Health Care
What the data says
ResMed's cost of revenue of $2.1B is higher than 76% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 9 consecutive years, from $772M in FY2016 to $2.1B in FY2025.
Based on SEC 10-K filings.
$2.1B in FY2025 with a 5-year CAGR of +11.0%. Top quartile in the Health Care sector.
Increased from $1.9B to $2.1B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +10.4%
- 5-Year CAGR
- +11.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 107This company $2.1B Sector average $11.8B
▼
-82.3% below sector average
Key checks
Key Insights
- ResMed's cost of revenue has grown for 9 consecutive years.
- 5-year CAGR of +11.0%, indicating consistent growth.
- In FY2025, cost of revenue increased 3.0% year-over-year.
- Ranks #26 out of 107 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1B | +3.0% |
| FY2024 | $2.0B | +8.7% |
| FY2023 | $1.9B | +20.2% |
| FY2022 | $1.6B | +14.4% |
| FY2021 | $1.4B | +9.6% |
| FY2020 | $1.2B | +11.4% |
| FY2019 | $1.1B | +10.7% |
| FY2018 | $1.0B | +16.2% |
| FY2017 | $865.0M | +12.0% |
| FY2016 | $772.2M | +15.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026